Jesse M. Cedarbaum MD
I am a Neurologist with a unique background of over 30 years of drug development and clinical trials experience in academia, biotechnology, large and small pharmaceutical companies. My therapeutic area expertise spans the spectrum of neuropsychiatric conditions, from neurodegenerative diseases (Alzheimer’s, Parkinson’s) to neuromuscular disorders (ALS, peripheral neuropathies) to psychiatric and ophthalmological disorders, and is represented in a body of over 100 peer-reviewed scientific publications. I have led cross-functional teams developing small molecule, protein and antisense therapeutics in all stages of the development process, including preclinical development, Phase 1, translational and “Proof of Concept” studies, Phase 3 clinical studies and associated regulatory activities. I have played key roles in the development of several currently marketed products, including Sinemet CR for treatment of motor response fluctuations in Parkinson’s disease, and Eyelea for the treatment of wet age-related macular degeneration and other retinal vascular conditions.
I obtained my medical degree from Yale Medical School, where I am currently Professor (Adjunct) of Psychiatry. After residency at New York Hospital-Cornell Medical Center I joined the Cornell faculty and led the Parkinson and Movement Disorders program at Burke Rehabilitation Center and the New York Hospital from 1983-1990. I then joined Regeneron, where I led the establishment of the clinical development function and served as Program Director and later Vice President of Clinical Affairs from 1990-2007. I subsequently held positions at Elan, Cytokinetics, and Bristol-Myers Squib. Most recently, I was most recently Sr. Distinguished Investigator at Biogen, leading a team focused on development of novel therapeutics for Parkinson’s disease and Movement Disorders.
I have authored or co-authored over 100 peer-reviewed scientific publications, most in the area of neurotherapeutics. I am a Fellow of both the American Academy of Neurology and the American Neurological Association. I am a recognized leader in pre-competitive activities supporting the advancement of neurotherapeutics, having served as the industry chair of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Advisory Board and the Industry Scientific Advisory Board (ISAB) for the Michael J Fox Foundation’s Parkinson Progression Markers Initiative (PPMI), and as Industry Co-Chair of the Critical Path for Parkinson’s consortium sponsored by the Critical Path Initiative and Parkinson’s UK.
COMTEC SPAIN
Bailen, 95 – 97
pral.1.a – 08009
Barcelona, Spain
Tel: +34-932081145
Fax: +34-934579291
spain-office@comtecmed.com
COMTEC CHINA
Suite 405, Universal Center Building
175 Xiang Yang Road South
Shanghai 200031, China
Tel: +86-21-54660460
Fax: +86-21-54660450
china-office@comtecmed.com
COMTEC USA
415 South Street
POB #3627
Waltham, MA 02453-2700
Tel: +1-914-312-5407
Fax: 972-3-566-6177
usa-office@comtecint.com